Catalent, Inc. (CTLT)
USD 63.48
(0.0%)
USD 63.48
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 6.14 Billion USD | 0.03% |
| 2023 | 6.14 Billion USD | 7.62% |
| 2022 | 5.71 Billion USD | 9.91% |
| 2021 | 5.19 Billion USD | 6.55% |
| 2020 | 4.87 Billion USD | 8.34% |
| 2019 | 4.5 Billion USD | 30.72% |
| 2018 | 3.44 Billion USD | 26.13% |
| 2017 | 2.73 Billion USD | 11.23% |
| 2016 | 2.45 Billion USD | -2.24% |
| 2015 | 2.51 Billion USD | -27.46% |
| 2014 | 3.46 Billion USD | -0.15% |
| 2013 | 3.46 Billion USD | -0.65% |
| 2012 | 3.48 Billion USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 6.14 Billion USD | -0.1% |
| 2024 Q2 | 6.3 Billion USD | 2.61% |
| 2024 FY | 6.14 Billion USD | 0.03% |
| 2024 Q4 | 6.14 Billion USD | -1.9% |
| 2024 Q3 | 6.26 Billion USD | -0.52% |
| 2023 FY | 6.14 Billion USD | 7.62% |
| 2023 Q3 | 6.12 Billion USD | -1.73% |
| 2023 Q4 | 6.14 Billion USD | 0.33% |
| 2023 Q2 | 6.23 Billion USD | 13.26% |
| 2023 Q1 | 5.5 Billion USD | -3.98% |
| 2022 Q2 | 5.72 Billion USD | -1.4% |
| 2022 Q3 | 5.69 Billion USD | -0.56% |
| 2022 FY | 5.71 Billion USD | 9.91% |
| 2022 Q1 | 5.8 Billion USD | 11.66% |
| 2022 Q4 | 5.73 Billion USD | 0.76% |
| 2021 Q3 | 4.69 Billion USD | 7.15% |
| 2021 FY | 5.19 Billion USD | 6.55% |
| 2021 Q1 | 4.3 Billion USD | -11.73% |
| 2021 Q2 | 4.38 Billion USD | 1.81% |
| 2021 Q4 | 5.19 Billion USD | 10.65% |
| 2020 Q3 | 4.28 Billion USD | 10.66% |
| 2020 Q1 | 3.86 Billion USD | -14.19% |
| 2020 Q2 | 3.87 Billion USD | 0.23% |
| 2020 Q4 | 4.87 Billion USD | 13.82% |
| 2020 FY | 4.87 Billion USD | 8.34% |
| 2019 Q1 | 2.97 Billion USD | -13.76% |
| 2019 FY | 4.5 Billion USD | 30.72% |
| 2019 Q4 | 4.5 Billion USD | 56.75% |
| 2019 Q3 | 2.87 Billion USD | -0.22% |
| 2019 Q2 | 2.87 Billion USD | -3.09% |
| 2018 Q3 | 3.48 Billion USD | 3.08% |
| 2018 Q4 | 3.44 Billion USD | -1.18% |
| 2018 FY | 3.44 Billion USD | 26.13% |
| 2018 Q1 | 2.74 Billion USD | 0.56% |
| 2018 Q2 | 3.38 Billion USD | 23.15% |
| 2017 Q1 | 2.51 Billion USD | 2.38% |
| 2017 FY | 2.73 Billion USD | 11.23% |
| 2017 Q3 | 2.64 Billion USD | 2.97% |
| 2017 Q4 | 2.73 Billion USD | 3.34% |
| 2017 Q2 | 2.56 Billion USD | 2.1% |
| 2016 FY | 2.45 Billion USD | -2.24% |
| 2016 Q4 | 2.45 Billion USD | 0.02% |
| 2016 Q3 | 2.45 Billion USD | 1.11% |
| 2016 Q2 | 2.42 Billion USD | -1.28% |
| 2016 Q1 | 2.45 Billion USD | -2.08% |
| 2015 Q2 | 2.54 Billion USD | 3.98% |
| 2015 Q1 | 2.44 Billion USD | -29.28% |
| 2015 FY | 2.51 Billion USD | -27.46% |
| 2015 Q4 | 2.51 Billion USD | 0.22% |
| 2015 Q3 | 2.5 Billion USD | -1.56% |
| 2014 Q2 | 3.48 Billion USD | 1.7% |
| 2014 Q1 | 3.42 Billion USD | -1.11% |
| 2014 FY | 3.46 Billion USD | -0.15% |
| 2014 Q4 | 3.46 Billion USD | -0.84% |
| 2014 Q3 | 3.49 Billion USD | 0.13% |
| 2013 Q4 | 3.46 Billion USD | 0.0% |
| 2013 FY | 3.46 Billion USD | -0.65% |
| 2013 Q1 | - USD | 0.0% |
| 2012 FY | 3.48 Billion USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 3.45 Billion USD | -78.1% |
| Bausch Health Companies Inc. | 27.43 Billion USD | 77.585% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -418.64% |
| Elanco Animal Health Incorporated | 8.13 Billion USD | 24.45% |
| Perrigo Company plc | 6.04 Billion USD | -1.784% |
| Teva Pharmaceutical Industries Limited | 35.35 Billion USD | 82.607% |
| Zoetis Inc. | 9.29 Billion USD | 33.846% |